Market Access

Market access: risk sharing and alternative pricing schemes

Shared-risk agreements can represent uncertain rewards for drug makers and payers. What you need to know before entering into one. read...

Market access: How to meet both marketing authorisation and HTA needs

Leela Barham looks at the costs and benefits of taking a more collaborative approach towards marketing authorisation and Health Technology Assessments. read...

New sales models and market access

John Ferguson explores new ways to update pharma sales methods to improve market access. read...

Is value-based pricing an aid to market access?

Leela Barham explores whether pharma firms can use value-based pricing (VBP) to improve market access. read...

The impact of value mining on market access

Peter Mansell explains how multiple stakeholders are analyzing data to make their own determinations of medicine value. read...

Personalized medicine comes one step closer

Researchers from the Stanford University School of Medicine have given us a glimpse of what the future of healthcare could look like. read...

The state of play in market access

Linda Banks reports on the highlights of eyeforpharma’s recent Market Access Europe conference.read...
Get Adobe Flash playerPlugin by wpburn.com wordpress themes